Kwality Pharmaceuticals Ltd · BSE:KPL
Kwality Pharmaceuticals — Investor Presentation (March 2022)
19 slides from Kwality Pharmaceuticals's investor presentation, March 2022
Slide 1: Kwality Pharma Investor Presentation
Kwality Pharma QUALITY YOU CAN TRUST Investor Presentation Financial Year March 2022
Slide 2: Executive Summary
Executive Summary
Slide 3: Kwality – A Niche Injectable Player for Emerging Markets
Kwality – A Niche Injectable Player for Emerging Markets Strong portfolio of 600 products and a Strong focus on complex injectables like pipeline of 300 products under India’s Leading injectable player with a Liposomal, peptide-based, protein- registration. strong presence in emerging markets based,
Slide 4: Kwality at a Glance: Overview
Kwality at a Glance: Overview Company overview Financial overview • About 500 450 ✓ Established in 1983, Kwality Pharmaceuticals is a leading exporter of 400 complex generics formulations with Injectables forming over 70% of its FY 350 22 sales. 300 ✓ Listed on the Bombay Stock Exchange (SME Segment
Slide 5: Kwality at a Glance: Evolution of the Company
Kwality at a Glance: Evolution of the Company • Started marketing office in Africa 2010 and new manufacturing in Jammu (HP) • New manufacturing with OSD and • PICs/GMP from Iran, Iraq and 2004 2018 injectable capabilities for general Tanzania therapies and beta lactam • New Cephalosporin facility in
Slide 6: Key Highlights
Key Highlights
Slide 7: Kwality: Key Highlights
Kwality: Key Highlights Development capabilities in complex products: Specialist capabilities, expertise, and know-how in Long-chain acting injectables, Liposomal injectables, Lipid nano particles/Lipid complexes, Lyophilized injectables, Protein-based injectables, and complex ophthalmic Highly expe
Slide 8: Development capabilities in complex injectables
Development capabilities in complex injectables Complex injectable drug products Key technologies involved Kwality experience • Sustained drug release • Reducing injection frequency Developed complex long-acting injectables: Leuprolide depot injectable, Octreotide Acetate Long-acting Injectables usi
Slide 9: Highly experienced leadership team
Highly experienced leadership team Mr. Ramesh Arora Mr. Ajay Arora Mr. Aditya Arora Managing Director Director Director • Founder of the company • Has been with the • Has been with the company for the past 28 company for the past 7 • Overall head of business years years with a focus on strategy and
Slide 10: Manufacturing facilities are approved by emerging markets…
Manufacturing facilities are approved by emerging markets… Locations Regulatory approvals Jassur, HP Amritsar, PB Locations Amritsar Jassur Units Unit-1 Unit-4* Unit-2 Unit-3 Therapy General Therapies Beta-lactum Oncology Cephalosporins Tablets, Capsules, Oral liquid, Sachets, Dry powder for suspens
Slide 11: ..and expected to get approved by high-end markets like Europe, Brazil and Mexico
..and expected to get approved by high-end markets like Europe, Brazil and Mexico Regulatory agency Region/countries Expected timeline of approvals • Country: Brazil • By Oct 2022 (General therapy section) and by Nov. 2022 (Oncology injection) • Brazil is among the top 15 pharmaceuticals market by c
Slide 12: Manufacturing facility: Few snapshots
Manufacturing facility: Few snapshots *under completion 12
Slide 13: Established presence in over 60 emerging markets through successful product registrations
Established presence in over 60 emerging markets through successful product registrations South and Central America Africa Middle East Asia Colombia Costa Rica Botswana Uganda Iran Egypt India Uzbekistan Guatemala El Salvador Kenya South Africa Iraq Algeria Sri Lanka Indonesia Namibia Tanzania Chile
Slide 14: Product registrations
Product registrations South and Latin America* Product registrations #’s Registered 72 South-East Asia Under registrations 77 Africa Product registrations #’s Product registrations #’s Registered 86 Registered 102 Under registrations 42 Under registrations 17 *Including Mexico and Brazil
Slide 15: Kwality of the Future: Focus on High Margin Portfolio & Commercial Partnerships
Kwality of the Future : Focus on HIGH MARGIN PORTFOLIO & Commercial Partnerships Focus on Niche high Building long term margin portfolio of Injectables would be the commercial partnerships difficult to manufacture growth driver both locally & globally molecules Continuing investments in Manufacturin
Slide 16: Superior Financials
Superior Financials
Slide 17: Profit & Loss Account
Profit & Loss Account For theyearending31st March(In Crores) FY19 FY20 FY21 FY22 Revenue fromoperations 166.29 139.30 262.01 456.19 Cost of GoodsSold 119.45 87.08 165.59 200.60 Gross profit 46.84 52.22 96.42 255.59 Gross profit% 28.17 37.49 36.80 56.02 EBITDA 16.31 17.85 30.44 175.17 EBITDA% 9.81 12
Slide 18: Balance Sheet
Balance Sheet EQUITY AND LIABILITIES FY 19 FY20 FY 21 FY22 Shareholders’ funds (a) Share capital 10.38 10.38 10.38 10.38 (b) Reserves and surplus 26.92 35.63 50.78 170.77 37.30 46.01 61.15 181.14 Minority Interest in Subsidiary -0.98 -1.04 -1.30 -1.35 Non-current liabilities (a) Long-term borrowings
Slide 19: 19
19
Kwality Pharmaceuticals — Investor Presentation (March 2022) on 6ix